Financial Survey: Prime Medicine (NYSE:PRME) versus Genocea Biosciences (NASDAQ:GNCAQ)

Prime Medicine (NYSE:PRME) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Profitability

This table compares Prime Medicine and Genocea Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-107.87%	-74.97%
Genocea Biosciences	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Prime Medicine and Genocea Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0	3	4	1	2.75
Genocea Biosciences	0	0	0	0	0.00

Prime Medicine currently has a consensus price target of $8.92, suggesting a potential upside of 56.98%. Given Prime Medicine’s stronger consensus rating and higher probable upside, research analysts clearly believe Prime Medicine is more favorable than Genocea Biosciences.

Institutional and Insider Ownership

70.4% of Prime Medicine shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Prime Medicine and Genocea Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.96 million	154.08	-$198.13 million	($1.56)	-3.64
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

Genocea Biosciences has lower revenue, but higher earnings than Prime Medicine.

Volatility & Risk

Prime Medicine has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.

Summary

Prime Medicine beats Genocea Biosciences on 8 of the 10 factors compared between the two stocks.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.